The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-human dose escalation study of LY2875358 (LY), a bivalent MET antibody, as monotherapy and in combination with erlotinib (E) in patients with advanced cancer.
Jonathan Wade Goldman
Honoraria - Lilly
Research Funding - Lilly
Lee S. Rosen
Research Funding - Lilly
Alain Patrick Algazi
No relevant relationships to disclose
Patricia Kellie Turner
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Volker Wacheck
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Jay Tuttle
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
James E Wooldridge
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Michaela S. Banck
No relevant relationships to disclose